Roslin Cell Therapies Ltd. (RoslinCT). (9/25/17). "Press Release: Roslin Cell Therapies Ltd. is Now Trading as RoslinCT".

	Organisation	Roslin Cell Therapies Ltd. (RoslinCT)
	Product	contract manufacturing (biologicals)
	Product 2	advanced therapeutic product (gene therapy, cell therapy, tissue engineering products)

Roslin Cell Therapies Ltd. is delighted to announce that the company has launched a new corporate branding strategy and website.

The new trade name, RoslinCT, elevates the corporate identity and supports the full range of contract services provided. RoslinCT is a Contract Development and Manufacturing Organisation (CDMO) offering process development, technology transfer, GMP manufacture and batch release of cell-based therapies and Advanced Therapy Medicinal Products (ATMP’s).

“We have successfully established our contract development and GMP manufacturing services, growing the business over the last few years and forming progressive partnerships with our clients to help bring cell therapies to the clinic” said Janet Downie, RoslinCT’s CEO. “It is important to us that our brand reflects and promotes our company in the field of regenerative medicine and highlights the value we add to our clients’ clinical programmes”.

An updated website is introduced at www.roslinct.com showcasing the services offered and introducing the team behind the new company identity.

About RoslinCT

RoslinCT has a vision to lead the field in cell and gene therapy manufacturing and be the global partner of choice, building success on expert knowledge, progressive partnerships and with drive to deliver life-changing cell-based products. This rebranding is a key part of the development and expansion of the business, where RoslinCT will expand its service offering and work in partnership with its clients to provide a route through to commercial manufacture.

RoslinCT strives to provide superior development and manufacturing services, combined with expert advice, value and support at every stage to those bringing the next generation advanced therapies to patients. This together with a passion for innovation and a flexible and personalised approach enables RoslinCT to support clients at every step of the cell therapy development journey.

END

For more information, please contact:

Fiona Bellot, Business Development Manager
Tel: +44 (0)131 658 5180
Mobile: +44 (0)7867494071
Email: fiona.bellot@roslinct.com
Web : www.roslinct.com

Record changed: 2020-06-28